Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Delisting risk
confidence 98%
filed 2026-08-14
Item 3.01
Adagio Medical received a deficiency letter from Nasdaq on August 13, 2026, notifying the company that it failed to maintain the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market. The company reported negative stockholders' equity of $(415,000) as of June 30, 2026, and does not meet alternative quantitative standards. The company has 45 calendar days to submit a compliance plan or face potential delisting. This is a clear notice of failure to satisfy a continued listing rule under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-08-14
EX-99.1
PS International Group Ltd. received an official Nasdaq deficiency letter dated August 12, 2026 for failure to maintain the minimum Market Value of Listed Securities (MVLS) of US$35 million and does not satisfy alternative continued listing criteria. The company has been granted a 180-calendar-day compliance period ending February 8, 2027, with explicit warning that failure to restore the required MVLS will result in formal delisting notification. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the registrant's continued trading status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-08-14
Item 3.01
Actinium Pharmaceuticals received notice of non-compliance with NYSE American continued listing standards (Sections 1003(a)(ii) and (iii)) on May 27, 2026, submitted a compliance plan on June 18, 2026, and on August 12, 2026 received acceptance of that plan with a plan period through November 27, 2027. The company's stock continues to trade on NYSE American subject to compliance with the plan, with explicit warning that failure to regain compliance or make progress consistent with the plan may result in delisting proceedings.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-14
Item 3.01
Teads received written notice from Nasdaq on August 11, 2026, that it failed to comply with Nasdaq Listing Rule 5450(a)(1) because its stock closing bid price has been below $1.00 per share for 30 consecutive business days. The company has been granted an initial 180-calendar-day compliance period (until February 8, 2027) to regain compliance, with the possibility of an additional 180-day period if it transfers to The Nasdaq Capital Market. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status and stock liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-14
Reed's received a notice from NYSE American on August 12, 2026, stating non-compliance with continued listing standards under Section 1003(a)(i) due to stockholders' deficit of $(1.5) million and losses in five consecutive fiscal years. The company has until November 29, 2027, to regain compliance or face delisting proceedings. The stock will trade with a ".BC" designation indicating "below compliance" status. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-14
Worksport Ltd. received written notice from Nasdaq on August 13, 2026, that it failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days until February 9, 2027, to regain compliance or face delisting. This is a classic Item 3.01 delisting-risk disclosure and is material to investors as it threatens the company's continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-08-14
Item 8.01
Beyond Meat announced a 1-for-30 reverse stock split intended to regain compliance with Nasdaq's minimum bid price requirement of $1.00 by August 31, 2026. The company faces material delisting risk if it fails to achieve the required minimum bid price, and there is no assurance the reverse split will be successful in maintaining continued listing on the Nasdaq Global Select Market.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-08-14
EX-99.1
The press release discloses receipt of a final action letter from Nasdaq dated August 11, 2026, informing Davis Commodities that the Nasdaq Board declined to review the Listing Council's July 28, 2026 decision to delist the Company's securities. Nasdaq will follow procedures under Listing Rule 5830 and SEC Rule 12d2-2 to remove the Company's securities from listing. Trading was already suspended on March 25, 2026, and shares now trade OTC under "DTCKF." This is a material delisting event that directly affects the registrant's listing status and investor access to the securities.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-14
Item 3.01
Optimum Communications received notice from the NYSE on August 13, 2026, that its Class A common stock has fallen below the $1.00 minimum average closing price requirement under NYSE Listed Company Manual Section 802.01C. The company has a six-month cure period (until February 13, 2027) to regain compliance; failure to do so will trigger NYSE procedures to suspend and delist the stock.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-14
Item 3.01
The NYSE has commenced delisting proceedings and immediately suspended trading in SES AI's warrants (ticker SES WS) due to abnormally low selling prices under NYSE Listed Company Manual Section 802.01D. While the Company's Class A common stock (SES) remains listed and unaffected, the delisting of the warrants represents a material loss of liquidity and trading access for warrant holders. This is a clear delisting notice triggering Item 3.01 disclosure obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-14
Item 3.03
Nerdy Inc. announced a 1-for-15 reverse stock split effective August 19, 2026, explicitly to regain compliance with the New York Stock Exchange's minimum average closing price requirement for continued listing. The company had fallen below the NYSE's minimum share price threshold and is taking this capital structure action to restore compliance and avoid delisting.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-13
Item 8.01
The filing discloses a Nasdaq minimum bid price compliance matter under Listing Rule 5550(a)(2). Although the Company has now regained compliance as of August 10, 2026, the disclosure documents the prior delisting risk period (November 2025 through August 2026) during which the stock failed to meet the $1 minimum bid price requirement and the Company was subject to two successive 180-day compliance periods. This is a material delisting-risk event, even though the immediate threat has been resolved.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-13
Item 8.01
TMRC's common stock was withdrawn from OTCQB trading, and the company announced its intention to file Form 15 for deregistration under Section 12(g) and suspension of SEC reporting obligations.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-12
EX-99.1
The exhibit discloses that AGM Group Holdings received a Nasdaq non-compliance notice on May 18, 2026, for failure to timely file its Form 20-F annual report, triggering Nasdaq Listing Rule 5250(c)(1) violation and delisting risk. The company subsequently filed the Form 20-F on August 7, 2026, and Nasdaq confirmed regained compliance on August 11, 2026. This is a material delisting-risk disclosure because it documents the company's prior non-compliance with continued listing standards and the remedial action taken to cure the violation.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-12
EX-99.1
The announcement discloses NOVONIX's failure to comply with Nasdaq's minimum bid price requirement (closing bid below US$1.00 for 30 consecutive business days as of 18 March 2026) and the Company's 180-day compliance period to regain compliance. The ADS ratio change from 1:4 to 1:40 is explicitly stated as intended to increase per-ADS trading price and assist in regaining compliance, directly addressing delisting risk. This is a material disclosure of a continued listing rule violation and the Company's remedial action.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-12
Item 3.01
Generation Income Properties received a Nasdaq delisting notice for failing to maintain the minimum $1.00 bid price for 30 consecutive business days and failing the minimum $1.0 million market value of publicly held shares requirement. The company has regained compliance with the minimum stockholders' equity rule ($2.5M) but is now subject to a mandatory one-year panel monitor, during which any future non-compliance will result in automatic delisting with no opportunity to submit a compliance plan.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-12
Item 3.01
CID Holdco received a Staff Determination from Nasdaq on August 6, 2026, to delist the Company's common stock pursuant to Nasdaq Listing Rule 5450(b)(2)(A) due to failure to maintain the minimum Market Value of Listed Securities ($50 million) requirement. The Company plans to appeal the determination by requesting a hearing before a Nasdaq Hearings Panel by August 13, 2026.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-12
EX-99.1
The press release announces that Hongli Group has regained compliance with Nasdaq's minimum bid price requirement ($1.00 per share) after previously receiving a deficiency notice on July 2, 2026. While the company has now cured the deficiency, the disclosure documents a material delisting risk event—the company was out of compliance with continued listing standards and faced potential delisting. This is material to investors as it directly affects the company's listing status and trading availability.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-12
EX-99.1
Farmmi received a Nasdaq deficiency notification on August 11, 2026, for failure to maintain the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has 180 calendar days (until February 8, 2027) to regain compliance or face potential delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, as it notifies investors of a material threat to continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-12
Item 8.01
The press release discloses a pending Nasdaq delisting hearing scheduled for August 20, 2026, with the Company's stock currently trading under a stayed delisting action. The disclosure explicitly states "The Company's timely hearing request has stayed the delisting action" and notes that the Panel may determine to delist the Company's securities. This is a material disclosure of delisting risk under Item 3.01 taxonomy, as it directly addresses the registrant's continued listing status and the threat of delisting pending a regulatory hearing.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-11
EX-99.1
The press release discloses receipt of a Nasdaq minimum bid price notice dated August 10, 2026, indicating the Company's ADS closing bid price has been below the $1.00 minimum for 33 consecutive business days. While the notification has no immediate effect, it triggers a 180-day compliance period (until February 8, 2027) under Nasdaq Listing Rule 5810(c)(3)(A), with potential delisting risk if compliance is not regained. This is a material disclosure of delisting risk under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-11
Item 3.01
Rocket One received a Nasdaq notification on August 6, 2026, that it failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until February 2, 2027) to regain compliance, with a potential additional 180-day cure period if certain conditions are met.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-11
Item 8.01
Beyond Meat announced a 1-for-30 reverse stock split explicitly "intended to help the Company regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market." The disclosure directly addresses delisting risk and the remedial action taken to address it. While the reverse split itself is a capital structure event, the material disclosure here centers on the company's failure to meet Nasdaq listing standards and the corrective measure, which is the hallmark of delisting_risk classification.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-08-10
Item 3.01
Faraday Future received written notice from Nasdaq on August 7, 2026, confirming that the Company has regained compliance with Listing Rule 5550(a)(2) after its Common Stock closing bid price remained at $1.00 per share or greater for 10 consecutive business days (July 24–August 6, 2026), formally closing the related compliance matter.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-10
Item 3.03
Tenon Medical implemented a 1-for-35 reverse stock split effective August 10, 2026, to meet Nasdaq's minimum $1.00 average closing price requirement for continued listing on the Nasdaq Capital Market. The reverse split was undertaken in direct response to delisting risk and represents a material event affecting the company's exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-10
Item 8.01
The filing discloses that CEA Industries received a Nasdaq compliance notice on May 7, 2026 for failure to hold an annual meeting within twelve months (Nasdaq Listing Rule 5620(a)), which is a continued listing requirement violation. Although the company subsequently regained compliance by holding its 2026 Special Meeting on July 22, 2026 and received confirmation on August 5, 2026, the core event is the delisting risk that materialized and was then remedied. This is material to investors as it directly affects the company's ability to maintain its Nasdaq listing.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-08-10
RedCloud Holdings received written notification from Nasdaq on August 10, 2026, that it failed to maintain the minimum market value of listed securities ($35,000,000) required under Nasdaq Listing Rule 5550(b)(2). The company has 180 calendar days until February 8, 2027, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-10
The filing discloses Netcapital's receipt of a Nasdaq notice (Item 3.01) granting an additional 180-day compliance period until February 1, 2027, to regain compliance with the minimum $1.00 per share bid price requirement. The company failed to regain compliance during the initial 180-day period (ending August 3, 2026) and faces delisting if it does not cure the deficiency by the deadline. This is a material delisting risk disclosure under Item 3.01, distinct from the concurrent amendments to convertible notes (Item 1.01) and unregistered equity issuances (Item 3.02).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-10
Item 3.01
NYSE American initiated a trading halt on June 25, 2026, due to concerns that Northann Corp. filed its 2025 Form 10-K without obtaining auditor approval and consent. The company acknowledges it cannot predict the timing or outcome of the Exchange's review or whether the trading halt will be lifted or further listing proceedings initiated.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-10
Item 3.01
Construction Partners is not compliant with Nasdaq Listing Rule 5605(c)(2)(A) because the death of independent director Michael H. McKay reduced the Audit Committee below the required minimum of three independent directors. The Company is relying on a cure period ending July 22, 2027 to restore compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-10
Item 3.01
Lexaria received a delisting notification from Nasdaq on August 4, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Although the company completed a reverse stock split and filed a hearing request to stay delisting, the core disclosure is a notice of delisting risk—the unmistakable signal that the registrant has failed a continued listing standard and faces suspension from trading absent successful appeal or compliance recovery.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-10
Item 3.03
Onfolio Holdings implemented a 1-for-50 reverse stock split to regain compliance with Nasdaq Capital Market Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The company disclosed that the reverse split was undertaken specifically to address delisting risk and restore compliance with Nasdaq's continued listing standards.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-08-07
Item 8.01
The filing discloses a Nasdaq minimum bid price compliance violation (Rule 5550(a)(2)) that triggered a 180-day cure period, followed by a second 180-day extension, and ultimately resolution through regaining compliance. While the final notification indicates the matter is closed, the disclosure documents the company's prior delisting risk and the compliance process, which is material to investors assessing listing status and stock price stability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-07
Item 3.01
Elutia received a formal notice from Nasdaq on August 6, 2026, that its Class A common stock closing bid price has fallen below the $1.00 minimum required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(a)(2). The company has been granted a 180-calendar-day compliance period (until February 2, 2027) to regain compliance, with explicit warning that failure to do so will result in delisting. This is a textbook delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-07
Item 3.01
Avalanche Treasury Corporation received deficiency letters from Nasdaq on August 6, 2026, for failure to meet both the Minimum Bid Price Requirement ($1.00 per share) and the Market Value of Listed Securities Requirement ($35 million). The company has been given 180-day compliance periods (until February 2, 2027) to cure these deficiencies, with explicit notice that failure to comply will result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-07
EX-99.1
Birks Group announces its intention to voluntarily delist from NYSE American LLC due to non-compliance with continued listing standards (Sections 1003(a)(i) and (ii) of the NYSE American Company Guide). The Company has filed a Form 25 effective August 17, 2026, with the last trading day expected around August 27, 2026. This is a material delisting event that directly affects the trading market and liquidity available to shareholders.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-07
The 6-K discloses that Nasdaq notified the Company on May 26, 2026 of non-compliance with Listing Rule 5250(c)(1) due to delayed filing of the Form 20-F, and that failure to regain compliance by November 11, 2026 will result in delisting of the Company's American Depositary Shares. This is a material delisting risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-07
Item 3.01
Arcadia Biosciences received a formal notice from Nasdaq on August 4, 2026, that it has failed to satisfy the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period until February 1, 2027, to regain compliance, with the explicit risk that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-07
Item 8.01
The filing discloses that Niki BioSolutions received a Nasdaq deficiency letter on March 5, 2026 for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), triggering a 180-day compliance period. The August 4, 2026 letter confirms the Company has regained compliance by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days. This is a delisting-risk disclosure—the Company faced potential delisting and has now resolved the deficiency, making it material to investors' assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-07
Xiao-I Corporation received a Nasdaq notification on August 6, 2026, that it failed to maintain the minimum market value of publicly held shares (MVPHS) of US$15,000,000 required under Nasdaq Listing Rule 5450(b)(3)(C). The company has been granted a 180-day compliance period (until February 1, 2027) to regain compliance, with explicit warning that failure to do so will result in delisting notification. This is a material disclosure of delisting risk under Item 3.01 equivalent.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-07
EX-99.1
The exhibit discloses receipt of a NYSE letter notifying AMTD IDEA that it is below compliance standards due to ADS trading price falling below US$1.00 over a 30 trading-day period. The Company has a six-month cure period; failure to regain compliance will trigger NYSE suspension and delisting procedures. This is a direct delisting risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-07
Item 3.01
HeartSciences received a Nasdaq notice on August 4, 2026, that it failed to comply with Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity. The company reported only $226,060 in stockholders' equity as of April 30, 2026, and does not meet alternative compliance metrics. Nasdaq has provided 45 days to submit a compliance plan, with potential delisting if the company fails to regain compliance. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-07
Item 3.01
The filing discloses a delisting-related matter under Item 3.01. Although the outcome is favorable—Nasdaq confirmed on August 3, 2026 that the Company "timely evidenced compliance with the $1.00 bid price requirement and all other applicable criteria for continued listing"—the disclosure itself concerns a material delisting risk that was previously pending. The Company had been required to meet a $1.00 minimum bid price for 20 consecutive trading sessions by July 30, 2026, and this 8-K documents the resolution of that compliance challenge. This is material to investors as it addresses the registrant's continued listing status on Nasdaq.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-07
AXIA Energia announced the commencement of ADR trading on the OTC market and the filing of Form 15F to terminate its SEC registration and suspend reporting obligations under Section 12(g) of the Securities Exchange Act of 1934, with deregistration expected to become effective 90 days after filing. This constitutes a material delisting event — the company is voluntarily withdrawing from SEC reporting and transitioning to OTC trading, which materially affects investor access to regulated disclosures and the registrant's listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-07
Item 3.01
Neonode received written notice from Nasdaq on August 6, 2026, that it failed to maintain the minimum $1.00 bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day grace period until February 2, 2027, to regain compliance, with the explicit warning that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-07
Item 3.01 discloses that Nasdaq notified Giftify on August 3, 2026, that the Company's closing bid price failed to maintain the minimum $1 per share requirement for 30 consecutive business days, triggering a 180-day cure period under Rule 5810(c)(3)(A). This is a direct delisting notice and a material threat to the Company's continued listing on Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-07
Eightco Holdings received a written notification from Nasdaq on August 5, 2026, that its common stock closing bid price fell below the $1.00 minimum required for continued listing on The Nasdaq Capital Market for 30 consecutive business days. The company has 180 calendar days until February 1, 2027, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-07
Item 3.01
Nasdaq has issued a definitive delisting determination effective August 12, 2026, citing the SEC's October 2025 trading suspension, delinquent Form 10-K and 10-Q filings, and the fact that the controlling shareholder (Society Pass, 78% voting power) filed for Chapter 11 bankruptcy on May 14, 2026. The company does not intend to appeal and will seek OTC quotation. This is a terminal delisting event, not merely a risk or notice of non-compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-06
Item 8.01
The Company discloses regaining compliance with Nasdaq continued listing requirements after previously failing to meet the minimum stockholders' equity standard of $2.5 million (May 21, 2026). While the disclosure is positive (resolution of delisting risk), the core event is the Company's prior non-compliance with listing standards and the subsequent remediation. This directly addresses delisting risk under Item 8.01, as the Company had been at material risk of delisting and has now satisfied the alternative MVLS Standard of $35 million in market value of listed securities.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 90%
filed 2026-08-06
Item 3.01
Olenox Industries disclosed a notice from Nasdaq regarding failure to satisfy the periodic filing requirement (Listing Rule 5250(c)(1)) due to late Form 10-K and Form 10-Q filings. The company regained compliance after filing the delinquent reports, with Nasdaq confirming restoration of compliance on August 4, 2026.
View raw filing on EDGAR →